Yezan Munther Haddadin's Insider Trades & SAST Disclosures
Yezan Munther Haddadin's most recent trade in Outlook Therapeutics Inc was a trade of 132,293 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Oct. 1, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Yezan Munther Haddadin.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Outlook Therapeutics Inc | Yezan Munther Haddadin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 132,293 | 132,293 | - | - | Stock Option (Right to Buy) | |
| Outlook Therapeutics Inc | Yezan Munther Haddadin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 56,636 | 56,636 | - | - | Stock Option (Right to Buy) | |
| Outlook Therapeutics Inc | Yezan Munther Haddadin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 19,771 | 19,771 | - | - | Stock Option (Right to Buy) | |
| Outlook Therapeutics Inc | Yezan Munther Haddadin | Director | Purchase of securities on an exchange or from another person at price $ 11.82 per share. | 28 Mar 2024 | 1,881 | 5,048 (0%) | 0% | 11.8 | 22,242 | Common Stock |
| Outlook Therapeutics Inc | Yezan Munther Haddadin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 94,441 | 94,441 | - | - | Stock Option (Right to Buy) | |
| Outlook Therapeutics Inc | Yezan Munther Haddadin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2023 | 41,065 | 41,065 | - | - | Stock Option (Right to Buy) | |
| Outlook Therapeutics Inc | Yezan Munther Haddadin | Director | Purchase of securities on an exchange or from another person at price $ 1.29 per share. | 06 Oct 2022 | 29,743 | 59,743 (0%) | 0% | 1.3 | 38,368 | Common Stock |
| Outlook Therapeutics Inc | Yezan Munther Haddadin | Director | Purchase of securities on an exchange or from another person at price $ 1.27 per share. | 06 Oct 2022 | 3,600 | 63,343 (0%) | 0% | 1.3 | 4,572 | Common Stock |
| Outlook Therapeutics Inc | Yezan Munther Haddadin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2022 | 71,998 | 71,998 | - | - | Stock Option (Right to Buy) | |
| Outlook Therapeutics Inc | Yezan Munther Haddadin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2022 | 21,878 | 21,878 | - | - | Stock Option (Right to Buy) | |
| Outlook Therapeutics Inc | Yezan Munther Haddadin | Director | Purchase of securities on an exchange or from another person at price $ 1.39 per share. | 02 Dec 2021 | 10,000 | 30,000 (0%) | 0% | 1.4 | 13,900 | Common Stock |
| Outlook Therapeutics Inc | Yezan Munther Haddadin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 47,335 | 47,335 | - | - | Stock Option (Right to Buy) | |
| Outlook Therapeutics Inc | Yezan Munther Haddadin | Director | Purchase of securities on an exchange or from another person at price $ 1.82 per share. | 19 Apr 2021 | 10,000 | 20,000 (0%) | 0% | 1.8 | 18,200 | Common Stock |
| Outlook Therapeutics Inc | Yezan Munther Haddadin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 20,873 | 20,873 | - | - | Stock Option (Right to Buy) | |
| Outlook Therapeutics Inc | Yezan Munther Haddadin | Director | Purchase of securities on an exchange or from another person at price $ 0.72 per share. | 22 Sep 2020 | 10,000 | 10,000 (0%) | 0% | 0.7 | 7,245 | Common Stock |
| Outlook Therapeutics Inc | Yezan Munther Haddadin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2020 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges